In Thursday’s Wall Street session, Black Diamond Therapeutics Inc (NASDAQ:BDTX) shares traded at $1.67, up 5.03% from the previous session.
BDTX stock price is now -20.88% away from the 50-day moving average and -54.13% away from the 200-day moving average. The market capitalization of the company currently stands at $94.63M.
With the price target of $20, Raymond James recently initiated with Outperform rating for Black Diamond Therapeutics Inc (NASDAQ: BDTX). , while ‘Stifel’ rates the stock as ‘Buy’
In other news, BIOTECH GROWTH N V, 10% Owner sold 5,784,292 shares of the company’s stock on Mar 19 ’25. The stock was sold for $11,997,749 at an average price of $2.07. Upon completion of the transaction, the 10% Owner now directly owns 2,733,547 shares in the company, valued at $4.57 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 28 ’24, 10% Owner Versant Venture Capital VI, L. sold 221,600 shares of the business’s stock. A total of $1,400,556 was realized by selling the stock at an average price of $6.32. This leaves the insider owning 3,726,341 shares of the company worth $6.22 million. A total of 23.86% of the company’s stock is owned by insiders.
During the past 12 months, Black Diamond Therapeutics Inc has had a low of $1.57 and a high of $7.66. As of last week, the company has a debt-to-equity ratio of 0.27, a current ratio of 4.92, and a quick ratio of 4.92. The fifty day moving average price for BDTX is $2.1106 and a two-hundred day moving average price translates $3.64035 for the stock.
The latest earnings results from Black Diamond Therapeutics Inc (NASDAQ: BDTX) was released for 2024-12-31.
